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Aims Succinate accumulates several-fold in the ischaemic heart and is then rapidly oxidized upon reperfusion, contribut-
ing to reactive oxygen species production by mitochondria. In addition, a significant amount of the accumulated suc-
cinate is released from the heart into the circulation at reperfusion, potentially activating the G-protein-coupled
succinate receptor (SUCNR1). However, the factors that determine the proportion of succinate oxidation or re-




To address these questions, we assessed the fate of accumulated succinate upon reperfusion of anoxic cardiomyo-
cytes, and of the ischaemic heart both ex vivo and in vivo. The release of accumulated succinate was selective and
was enhanced by acidification of the intracellular milieu. Furthermore, pharmacological inhibition, or haploinsuffi-
ciency of the monocarboxylate transporter 1 (MCT1) significantly decreased succinate efflux from the reperfused
heart.
....................................................................................................................................................................................................
Conclusion Succinate release upon reperfusion of the ischaemic heart is mediated by MCT1 and is facilitated by the acidification
of the myocardium during ischaemia. These findings will allow the signalling interaction between succinate released
from reperfused ischaemic myocardium and SUCNR1 to be explored.
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1. Introduction
Succinate accumulates several-fold in a range of ischaemic tissues, includ-
ing the heart.1–5 Upon reperfusion, the succinate levels very rapidly
(<1.5–2 min) return to baseline values.3,4 A proportion of this accumu-
lated succinate is oxidized by the mitochondrial respiratory chain, con-
tributing to the formation of the reactive oxygen species (ROS),
superoxide (Figure 1).4 This ROS production initiates a cascade of
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damage that culminates in ischaemia/reperfusion (I/R) injury.4 In addition
to its oxidation, upon reperfusion a significant amount of the accumu-
lated succinate is released from the heart into the circulation.2,6 The suc-
cinate accumulated during ischaemia is thought to move from the
mitochondria to the cytosol, catalysed by the dicarboxylate carrier in ex-
change for malate.7 Therefore, upon reperfusion of the ischaemic heart,
the cytosolic succinate has two fates—it either re-enters mitochondria
as a respiratory substrate to drive ROS production or effluxes from the
cell (Figure 1). Efflux of succinate from the ischaemic heart upon reperfu-
sion has been demonstrated ex vivo in the mouse heart and in human
hearts in vivo during primary percutaneous coronary intervention on ST-
elevated myocardial infarction (STEMI) patients.2,6 However, the mecha-
nism of succinate release is unknown.
Succinate accumulation is a conserved signature of ischaemia in differ-
ent organs and species,1–5 suggesting that its release upon reperfusion
may be a signal of tissue ischaemia and/or damage. Furthermore, there is
a G-protein-coupled succinate receptor (SUCNR1) that can respond to
the succinate released into the circulation (Figure 7).8–10 SUCNR1 is
highly expressed on the surface of immune cells and its ligation has been
associated with a range of both pro- and anti-inflammatory phenotypes,
depending on context.8,11–13 In addition, succinate release into the circu-
lation may have other effects in addition to signalling from ischaemic tis-
sue, for example, succinate was shown to activate thermogenesis by
brown adipose tissue.14 Together these findings suggest that succinate
released from ischaemic tissues into the circulation may promote a range
of responses, such as the infiltration of immune cells and thereby con-
tribute to the pathology and/or resolution of I/R injury (Figure 7).6,9,15
To address the mechanism of succinate release into the circulation
during reperfusion, we assessed the efflux of succinate from ischaemic
cardiomyocytes, mouse hearts ex vivo and in vivo, and in a pig model of
myocardial infarction (MI). We show that succinate was one of only a
few metabolites released upon reperfusion of the ischaemic heart.
Furthermore, succinate efflux was mediated by the monocarboxylate
transporter 1 (MCT1) and acidification of the myocardium during ischae-
mia enhanced release upon reperfusion. This understanding of how suc-
cinate is released upon reperfusion of ischaemic organs has translational
implications for targeting succinate signalling following MI.
2. Methods
All experiments were performed under UK Home Office Licences and
conducted according to the Animals Scientific Procedures Act 1986
(UK) and directive 2010/63/EU of the European Parliament guidelines on
the protection of animals used for scientific purposes. All experiments
were approved by the Institutional Animal Welfare and Ethical Review
Body. C57BL/6J male mice (25 g, 8–12 weeks old, n = 102) were from
Charles River, UK. The MCT1þ/- mice (8–12 weeks old) were initially
generated by homologous recombination16 and bred to produce
MCT1þ/- and corresponding MCT1þ/þ littermate controls. Female
Wistar rats (250 g, 10–12 weeks old) were from Charles River, UK. All
mice and rats were kept in individually ventilated cages with a 12 h light–
dark cycle, controlled humidity and temperature (20–22C), fed stan-
dard chow and water ad libitum. Experiments in pig were carried out un-
der Home Office Project Licence No 7008975 at the University of
Bristol Translational Biomedical Research Centre (TBRC), Bristol, UK,
an advanced facility for large animal research (http://www.bristol.ac.uk/
health-sciences/research/tbrc/).
For Langendorff perfusions, mice were administered terminal anaes-
thesia via intra-peritoneal pentobarbitone injection (140 mg/kg body
weight). For in situ I/R, mice were anaesthetized with isoflurane
(2minimum alveolar concentration and O2 at 2 L/min Abbott
Figure 1 Schematic of metabolite changes occurring during reperfusion. Upon reperfusion, succinate is oxidized producing ROS fed by succinate re-
entry into mitochondria. We favour RET at complex I as the mechanism of this ROS production. Some of the succinate is also released from the cell.
DIC, dicarboxylate carrier; FH, fumarate hydratase; IMM, inner mitochondrial membrane; IMS, inter-membrane space; I/R, ischaemia/reperfusion; OMM,
outer mitochondrial membrane; RET, reverse electron transport; ROS, reactive oxygen species; SDH, succinate dehydrogenase; TCA, tricarboxylic acid.

































































































Laboratories, USA) before performing a laparotomy and administering
100mL heparin bolus (100 iU; Leo Pharma A/S, Denmark). Mice were
culled via exsanguination by division of the abdominal inferior vena cava
(IVC) and aorta. For the acute murine MI model, mice were anaesthe-
tized throughout the procedure with sodium pentobarbital (70 mg/kg
body weight) and culled via exsanguination by division of the abdominal
IVC. For isolation of adult cardiomyocytes, mice were culled by cervical
dislocation (no anaesthetic used). For isolation of rat heart mitochondria
(RHM), rats were culled by cervical dislocation (no anaesthetic used). In
porcine MI model, landrace female pigs were premedicated with intra-
muscular injection of ketamine (10 mg/kg) and dexmedetomidine (15mg/
kg); for general anaesthesia, IV boluses of propofol (1 mg/kg) were used
followed by isoflurane in oxygen with the vaporizer set at 2% for mainte-
nance. At the end of the experiment, pigs were terminated by adminis-
tration of 2 L cold cardioplegia solution via the aorta at a delivery
pressure of 300 mmHg.
2.1 Animal I/R experimental models
2.1.1 Langendorff-perfused mouse hearts
Mice were administered terminal anaesthesia via intra-peritoneal pento-
barbitone injection (140 mg/kg body weight). While anaesthetics such
as pentobarbitone can affect mitochondrial function, in our experiments
the effects of inhibitors and other interventions are compared with con-
trols using identical anaesthetic regimes. Beating hearts were rapidly ex-
cised, cannulated, and perfused in isovolumic Langendorff mode at
80 mmHg pressure maintained by an St. Thomas Hospital (STH) peristal-
tic pump controller feedback system (AD Instruments, UK), with
phosphate-free Krebs–Henseleit (KH) buffer continuously gassed with
95% O2/5% CO2 (pH 7.4, 37C) containing (in mM) NaCl (116), KCl
(4.7), MgSO4.7H2O (1.2), NaHCO3 (25), CaCl2 (1.4), and glucose (11).
Cardiac function was assessed using a fluid-filled cling-film balloon
inserted into the left ventricle (LV) connected via a line to a pressure
transducer and a Powerlab system (AD Instruments). The volume of the
intraventricular balloon was adjusted using a 1.0 mL syringe to achieve an
initial LV diastolic pressure (LVDP) of 4–9 mmHg. Functional parameters
[systolic pressure (SP), end-diastolic pressure (DP), heart rate, coronary
flow, perfusion pressure] were recorded using LabChart software v.7
(AD Instruments) throughout the experiment. LVDP was calculated
from the difference between SP and DP. After 20 min equilibration,
hearts were subjected to 20 min global ischaemia prior to reperfusion.
Perfusate was collected in 1 min intervals for the first 6 min of reperfu-
sion and snap frozen in liquid nitrogen. Where inhibitors were used,
these were added in the reperfusion buffer, with the heart reperfused
for 6 min containing the inhibitors throughout (unless specified other-
wise). Hearts were immediately clamp frozen using Wollenberger tongs
pre-cooled in liquid nitrogen either after equilibration, ischaemia, or the
reperfusion period (6 min) and stored at –80C until further analysis.
2.1.2 In situ mouse heart I/R
Mice were anaesthetized with isoflurane (2minimum alveolar concen-
tration and O2 at 2 L/min; Abbott Laboratories) before performing a lap-
arotomy and administering 100mL heparin bolus (100 iU; Leo Pharma A/
S). Mice were exsanguinated by division of the abdominal IVC and aorta.
Global ischaemia was maintained within the body for 20 min, with
physiological temperature (37C) maintained using a core-temperature
controlled heating-mat. During ischaemia, fine borosilicate tubing was
inserted into the root of the aorta and a collection tube inserted into the
IVC lumen. Immediately before reperfusion, the superior vena cava,
pulmonary artery, and haemiazygos vein were clamped to prevent back
flow from the right atrium on flush. The heart was retrograde perfused
with phosphate-free KH buffer (37C) at a flow rate of 1 mL/min.
Perfusate was collected at 1 min intervals for 6 min and the heart clamp
frozen.
2.1.3 Porcine MI model
Landrace female pigs (n = 3; 5–6 months, median weight 62.5 kg) were
premedicated with intramuscular injection of ketamine (10 mg/kg) and
dexmedetomidine (15mg/kg); for general anaesthesia, IV boluses of pro-
pofol (1 mg/kg) were used followed by isoflurane in oxygen with the va-
porizer set at 2% for maintenance. Mechanical ventilation targets of tidal
volume of 10–20 mL/kg and a respiratory rate of 10–20 breaths/min
were used, aiming for end-tidal carbon dioxide between 35 and
45 mmHg. Full monitoring included electrocardiogram, invasive arterial
blood pressure, temperature, saturation, and central venous pressure via
a line in the central jugular vein (JV). Following median sternotomy and
heparinization (150 IU/kg), a 5–0 prolene suture was passed around the
proximal left anterior descending (LAD) artery just distal to the first di-
agonal branch; a catheter was inserted into the coronary sinus (CS) un-
der direct vision and a sampling line was inserted into the aortic root
(AR). Under stable conditions the LAD was gently snared to start a pe-
riod of 60 min of ischaemia, after which the snare was released to allow
reperfusion for another period of 60 min before termination and myo-
cardial sampling. Blood was drawn serially from JV, CS, and AR at the fol-
lowing time points: baseline, before intervention, and at 5, 15, 30, and
60 min during ischaemia and at 1, 3, 5, 15, 30, and 60 min of reperfusion.
2.1.4 In vivo murine MI model
The LAD coronary artery was occluded to induce MI in an acute open
chest, in situ mouse model as described previously17 to assess the effects
of AR-C141990 on I/R injury. Briefly, mice were anaesthetized by admin-
istration of sodium pentobarbital (70 mg/kg intraperitoneally), endotra-
cheally intubated, ventilated with 3 cm H2O positive end-expiratory
pressure and kept at 37C using a rectal thermometer-controlled heat-
pad (TCAT-2LV, Physitemp, USA).
Ventilation frequency was maintained at 110 breaths/min, with tidal
volume between 125 and 150mL. The heart was exposed and a suture
was placed around the prominent branch of the LAD and passed
through a small plastic tube used to initiate ischaemia by pressing the
tube against the heart surface to occlude the LAD. Mice were subjected
to 30 min of ischaemia and 120 min of reperfusion, after reperfusion,
hearts were stained with Evans Blue and 2% triphenyltetrazolium chlo-
ride and blindly analysed by an independent researcher.
2.2 Cardiomyocyte I/R model
2.2.1 Isolation of adult primary mouse cardiomyocytes
Adult primary mouse cardiomyocytes were isolated as described previ-
ously.18 Mice were culled by cervical dislocation before rapidly excising
the heart and cannulating via the aorta in ice-cold, sterile perfusion buffer
[in mM: NaCl (113), KCl (4.7), KH2PO4 (0.6), Na2HPO4 (0.6),
MgSO4.7H2O (1.2), NaHCO3 (12), KHCO3 (10), HEPES sodium salt
(0.922), taurine (30), 2,3-butanedione monoxime (10), and glucose
(5.5)]. Hearts were retrogradely perfused for 5 min with perfusion buffer
(37C) to clear residual blood, then the hearts were digested by perfus-
ing digestion buffer [30 mL perfusion buffer supplemented with 5 mg
Liberase (Roche, UK) and 12.5mM CaCl2] for 20 min. After digestion,
the heart was removed from the cannula and carefully broken apart with

































































































tweezers and gentle pipetting in 4 mL digestion buffer. The cell suspen-
sion was transferred to a 15 mL centrifuge tube before making up to
10 mL with stop buffer (37C) [10% (v/v) foetal bovine serum in perfu-
sion buffer] and allowed to pellet by gravity for 10 min at RT. After pel-
leting, the supernatant was removed and the cells were resuspended in
sequentially increasing Ca2þ concentrations (62mM, then 212mM, then
1 mM) in 5 mL stop buffer. Cells were subsequently resuspended in
M199 media (Gibco, Thermo Fisher Scientific) supplemented with 2 mM
L-carnitine, 5 mM creatine, 5 mM taurine, 25mM blebbistatin, 100 IU/mL
penicillin, and 100 IU/mL streptomycin and plated (1 105 cells/dish) in
laminin-coated (0.1 mg/mL from Engelbreth–Holm–Swarm murine sar-
coma basement membrane; Sigma Aldrich, UK) glass dishes.
2.2.2 Anoxic cardiomyocyte incubations
Anoxic incubations were carried out using an anaerobic chamber
(0.4 ppm O2; Belle Technologies, UK). Equipment and solutions were
degassed overnight in the transfer compartment of the anoxic chamber
before the experiment was performed.
Experiments were performed in Tyrode’s buffer [in mM: NaCl (137),
KCl (5.4), MgCl2 (0.4), HEPES (10), glucose (10), CaCl2 (1), pH 7.4]. The
MCT1 inhibitor (MCTi) AR-C141990 (Tocris, Biotechne) was used at a
concentration of 10mM in Tyrode’s buffer. Cardiomyocytes were plated
(1 105 cells/plate), washed once with Tyrode’s buffer (37C) before
2 mL fresh Tyrode’s buffer were added to each dish. Anoxia was induced
for different time points by placing dishes in the anaerobic chamber on a
37C heat block, before the cells were lysed under anoxia, transferred
to Eppendorf tubes and snap frozen on dry ice. Cells were reperfused by
removing from the anaerobic chamber, replacing buffer with fresh
Tyrode’s buffer and incubating (37C, 15 min) before lysing cells for sub-
sequent succinate analysis.
2.3 Metabolite measurement by mass
spectrometry
2.3.1 Succinate extraction
For tissue samples, frozen tissues were weighed out on dry ice to
achieve 25 mg of each tissue sample. Tissues were extracted with
25mL/mg MS extraction buffer [50% (v/v) methanol, 30% (v/v) acetoni-
trile, and 20% (v/v) H2O], supplemented with 1 nmol of [
13C4]-succinate
(Sigma Aldrich) in a pre-chilled Precellys tube (hard tissue homogenizing
CK28-R—2 mL; Bertin Instruments, France). Tissues were homogenized
using a Precellys 24 tissue homogenizer (6500 rpm, 15 s; Bertin
Instruments) and then immediately placed back on dry ice for 5 min.
Samples were re-homogenized (6500 rpm, 15 s) and again placed on dry
ice to cool before agitating in a shaking heat block (1400 rpm, 15 min,
4C; Thermo Fisher Scientific, UK) in a cold room (4C) and then incu-
bating (-20C, 1 h). Samples were subsequently centrifuged (17 000 g,
10 min, 4C) and the supernatant transferred to a pre-chilled microcen-
trifuge tube and recentrifuged (17 000 g, 10 min, 4C). The resulting
supernatants were transferred to pre-cooled MS vials which were stored
at -80C until analysis for succinate by liquid chromatography–tandem
mass spectrometry (LC–MS/MS).
For perfusate from the Langendorff heart and plasma samples, the
perfusate or plasma was centrifuged (17 000 g, 10 min, 4C) before
extracting 50mL in 750mL MS extraction buffer supplemented with
1 nmol [13C4]-succinate. The samples were agitated in the cold
(1400 rpm, 15 min, 4C; Thermo Fisher Scientific) before incubating
(-20C, 1 h). The samples were centrifuged (17 000 g, 10 min, 4C),
then the supernatant transferred to a new tube and recentrifuged. The
clear supernatant was transferred to MS vials and stored at -80C until
analysis.
For adult primary cardiomyocytes, cardiomyocytes were extracted in
500mL MS extraction buffer supplemented with 1 nmol [13C4]-succinate
and agitated in the cold (1400 rpm, 15 min, 4C; Thermo Fisher
Scientific) before incubating (-20C, 1 h). The samples were centrifuged
(17 000 g, 10 min, 4C), then the supernatant transferred to a new
tube and recentrifuged. The clear supernatant was transferred to MS
vials and stored at -80C until analysis.
2.3.2 Quantification of succinate
LC–MS/MS analysis of succinate was performed using an LCMS-8060
mass spectrometer (Shimadzu, UK) with a Nexera X2 UHPLC system
(Shimadzu). Samples were stored in a refrigerated autosampler (4C)
before injection of 5 lL using a 15lL flowthrough needle. Separation
was achieved using a SeQuantVR ZICVR -HILIC column (3.5lm, 100 Å,
150 mm 2.1 mm, 30C column temperature; MerckMillipore, UK)
with a ZICVR -HILIC guard column (200 Å, 1 mm 5 mm). A flow rate of
200lL/min was used with mobile phases of buffer A: 10 mM ammonium
bicarbonate and buffer B: 100% acetonitrile. A gradient of 0–0.1 min,
80% MS buffer B; 0.1–4 min, 80–20% B; 4–10 min, 20% B, 10–11 min, 20–
80% B; 11–15 min, 80% B was used. The mass spectrometer was oper-
ated in negative ion mode with multiple reaction monitoring and spectra
were acquired using LabSolutions software (Shimadzu), with compound
quantities calculated from relevant standard curves in MS extraction
buffer and comparing against [13C4]-succinate internal standard.
2.3.3 Metabolomic analysis by LC–MS
Samples were extracted as for succinate quantification but 13C-succinate
omitted and 5mM d8-valine added instead. LC–MS analyses were per-
formed on a Q Exactive Orbitrap (Thermo Scientific) mass spectrome-
ter coupled to an Ultimate 3000 UHPLC system (Dionex). The LC
system was fitted with either a ZIC-HILIC column (150 mm  4.6 mm)
or a ZIC-pHILIC column (150 mm  2.1 mm) and respective guard col-
umns (20 mm  2.1 mm) (all Merck, Germany). The metabolites were
eluted with previously described gradients.19 The mass spectrometer
was operated in full MS and polarity switching mode. Samples were ran-
domized in order to avoid bias due to machine drift and processed
blindly. The acquired spectra were analysed using XCalibur Qual and
XCalibur Quan Browser software (Thermo Fisher Scientific) by
referencing to an internal library of compounds.
2.4 Isolation of rat heart mitochondria
Rat heart mitochondria (RHM) were isolated as described previously.20
Briefly, freshly excised rat hearts were homogenized in STEB buffer
[250 mM sucrose, 5 mM Tris, 1 mM EGTA, 0.1% (w/v) bovine serum al-
bumin (BSA), pH 7.4] using a Dounce homogenizer. Homogenates were
centrifuged (3000 g, 5 min, 4C) to pellet nuclei and unbroken cells.
The resulting supernatant was then centrifuged (10 000 g, 10 min,
4C) to pellet mitochondria. Pelleted mitochondria were resuspended
in STEB buffer and recentrifuged (10 000 g, 10 min, 4C). The pelleted
mitochondria were resuspended in STEB buffer with the BSA omitted
(400mL/heart) and the mitochondrial protein quantified by bicinchoninic
(BCA) assay (Thermo Fisher Scientific).

































































































2.5 Measurement of ROS production by
RET
ROS production by reverse electron transport (RET) was measured by
following the conversion of Amplex Red to resorufin.20 Isolated RHM
were incubated in KCl buffer (120 mM KCl, 10 mM HEPES, 1 mM EGTA,
pH 7.4; 37C) supplemented with Amplex Red (12.5mM; Invitrogen,
Thermo Fisher Scientific), horseradish peroxidase (20mg/mL), BSA
(200mg/mL), superoxide dismutase (40mg/mL), and succinate (0–
10 mM) in a 96-well plate. Resorufin fluorescence was detected by kex=
570 nm and kem= 585 nm and calibrated against known concentrations
of hydrogen peroxide (46.6 M-1cm-1 at 240 nm).
2.6 Statistics and experimental design
All data in figures are presented as mean ± standard error of the mean
(SEM), unless stated otherwise in the figure legend. Statistical analysis
was performed using either one- or two-way ANOVA with the suitable
post hoc correction for multiple comparisons described in the figure leg-
end. Where only two groups were compared, statistical significance was
assessed by two-tailed Student’s unpaired t-test. A P-value of <0.05 was
considered significant. Statistics were calculated in Prism 8.0 software
(GraphPad Software Inc., USA).
3. Results
3.1 Succinate efflux upon reperfusion of an
ex vivo ischaemic heart
To quantify succinate efflux from the ischaemic heart upon reperfusion,
we used the Langendorff isolated heart perfusion model. Mouse hearts
following 20 min functional equilibration (LVDP 94± 3 mmHg, heart rate
453 ± 20 b.p.m., coronary flow 3.5± 0.14 ml/min mean ± SEM, n = 17)
were then exposed to 20 min global, no-flow ischaemia, followed by re-
perfusion with oxygenated perfusion buffer (Figure 2A). Langendorff
hearts exposed to ischaemia led to a 14-fold increase in succinate levels
(Figure 2B), comparable to the succinate accumulation seen previously in
the ischaemic heart in vivo.4,5 Upon subsequent reperfusion, tissue succi-
nate levels returned to baseline (Figure 2B). Halving the ischaemic time
decreased succinate accumulation, but following reperfusion the levels
of succinate were the same (Figure 2B). To see if any of the succinate that
had accumulated during ischaemia was released from the heart upon re-
perfusion, we next measured succinate in the coronary effluent immedi-
ately after reperfusion (Figure 2A). Succinate was released from the
myocardium into the circulation over the first 2 min of reperfusion, with
little further release after 3 min (Figure 2C). Note that the quantification
of succinate release is normalized to perfusate volume and is thus inde-
pendent of the flow rate. Comparing the total amount of succinate in the
perfusate to that in the heart at the onset of ischaemia, and correcting
for baseline levels, showed that about half of the succinate accumulated
during ischaemia was released (Figure 2C and D), as was shown previously
by Brookes and colleagues.6 To confirm that this succinate efflux was
largely from the cardiomyocytes, we used a murine primary adult cardio-
myocyte model exposed to anoxia and reperfusion. Succinate accumu-
lated significantly in anoxic cardiomyocytes and returned to baseline
levels upon reperfusion (Figure 2E). After reperfusion, 1.3± 0.25 nmol
succinate/105 cells (mean ± SEM, n = 6) was released into the incubation
medium. This succinate release is 60% of that accumulated within the
cardiomyocytes during ischaemia (corrected for succinate remaining
after reperfusion; Figure 2E) and is consistent with the amount released
from the heart upon reperfusion (Figure 2C and D).
3.2 Dependence of ROS production by RET
on succinate concentration
In our ex vivo system we found that after 20 min global ischaemia, the
level of succinate per heart increased to 360–400 nmol succinate/
heart, while in a previous study we found that 30 min global ischaemia of
the heart in situ leads to 800 nmol succinate/heart.5 As the mouse
hearts used in these studies weigh 184 ± 16 mg (n = 8, mean ± SEM),
this corresponds to 2–4mmol succinate/g wet weight. The water content
of the rodent heart is 615mL/g wet weight intracellular and 174mL/g wet
weight extracellular.21 Assuming that the succinate stays within the cells
during ischaemia and is distributed roughly equally throughout the cell,
this corresponds to an intracellular succinate concentration of 3–6 mM
at the onset of reperfusion. Even if during ischaemia the succinate was
also equally distributed between the intracellular and extracellular water,
this would still give an intracellular succinate concentration of 2.5–5 mM
at the onset of reperfusion. The level of succinate in the normoxic
mouse hearts here is 22 ± 3 nmol/heart (mean ± SEM n
= 5) and previously we reported a succinate level in the normoxic
mouse heart of 34 nmol/heart.5 This corresponds to normoxic succinate
levels of 120–185 nmol/g wet weight or an intracellular succinate con-
centration of 195–300mM. Thus, even if we assume that the efflux of
50% of the intracellular succinate occurred immediately upon reperfu-
sion, this would still leave mitochondria exposed to 1.5–3 mM succinate
at the onset of reperfusion, decreasing down to 200–300mM after 2–
3 min. To see if these levels of succinate were sufficient to drive RET at
complex I, we determined the dependence of complex I ROS produc-
tion by RET in isolated heart mitochondria on succinate concentration
(Figure 2F). This showed that RET production driven by succinate satu-
rated at 4 mM with a half-maximal effective concentration (EC50) of
1 mM (Figure 2F). This ROS production was largely inhibited by the
complex I inhibitor rotenone, which blocks RET but does not affect ROS
production at complex III. This is consistent with the protective effect of
rotenone on IR injury/infarct size and suggests that the ROS production
measured here is essentially all generated by RET at complex I. Thus, the
level of succinate present within the ischaemic heart at the onset of re-
perfusion is more than adequate to generate ROS by RET and this level
of succinate must decrease by 80% before substantially affecting RET.
Thus, the efflux of succinate from the tissue upon reperfusion does not
impact on its ability to drive RET and cause pathological I/R injury.
3.3 Selectivity of succinate release upon
reperfusion
To determine whether the succinate release from the heart was selec-
tive, or part of a general metabolite release due to tissue damage upon
reperfusion, the metabolome of the perfusate from the Langendorff
hearts was assessed (Figure 3A). For this, we could quantify the levels of
47 metabolites in the perfusate from the normoxic heart under equili-
bration, as well as in the perfusate during the first 3 min reperfusion of
the ischaemic heart (Figure 2A). We calculated the cardiac release ratio,2
the difference in metabolite levels between reperfusion and normoxia,
normalized to the levels in the normoxic effluent (Figure 3A). This
showed that only a few of the 47 metabolites measured were released
upon reperfusion. To assess this further, we plotted the differences in
metabolites in the perfusate between reperfusion and normoxia
(Figure 3B). This demonstrated that only 10 metabolites showed a
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Figure 2 (A–F) Succinate accumulation and efflux from the ischaemic Langendorff heart and primary cardiomyocytes. (A) Langendorff model experimental
design of ischaemia and reperfusion. (B) Time-dependent succinate accumulation in a Langendorff-perfused mouse heart exposed to 10 or 20 min global no-
flow ischaemia ± 6 min reperfusion (mean ± SEM, n = 3–8). Statistical significance was assessed by one-way ANOVA with Tukey’s post hoc test (**P < 0.01,
****P < 0.0001 *relative to equilibration, ####P < 0.0001 #relative to 10 min ischaemia). (C and D) Succinate efflux from the Langendorff heart exposed to
10 or 20 min ischaemia over the first 6 min of reperfusion (C) and compared to the succinate levels achieved in the heart exposed to 20 min ischaemia (D)
(mean ± SEM, n = 5–8). (E) Succinate accumulation and efflux in primary cardiomyocytes exposed to anoxia (1 h) ± reperfusion (15 min) (mean ± SEM,
n = 4–6). Statistical significance was assessed by one-way ANOVA with Dunnett’s post hoc test ****P < 0.0001, relative to control (Ctl) values. (F) ROS pro-
duction by RET in isolated heart mitochondria. Isolated RHM were incubated with varying succinate concentrations and where indicated rotenone (0.5mM),
and the production of H2O2 measured by the conversion of Amplex Red to resorufin (mean ± SEM, n = 3). The EC50 for the dependence of ROS produc-
tion by RET on succinate concentration is shown.





















































statistically significant release upon reperfusion. Among these were nico-
tinamide and the adenine nucleotide breakdown products hypoxanthine,
adenine, and inosine which are known to accumulate during ischae-
mia.4,5,22 These metabolites are all neutral so they may diffuse passively
through the cell membrane.23 In contrast, the other metabolites re-
leased—succinate, lactate, and some amino acids—are charged and will
require transporters to leave the cell upon reperfusion. Among charged
substrates the cardiac release ratio was highest for succinate (Figure 3A),
indicating that succinate is a major charged metabolite released upon re-
perfusion of the ischaemic tissue probably via a selective transport
pathway.
As the Langendorff heart is perfused with an oxygenated, hyperglycae-
mic crystalloid buffer, we were uncertain how this might affect succinate
accumulation, efflux, and consumption upon reperfusion compared to
the in vivo situation. To address this potential concern, we assessed
mouse hearts that were rendered ischaemic in situ, prior to which they
had been supplied with normal blood. To do this we induced global no-
flow ischaemia by exsanguination and then left the heart in the body for
20 min maintained at 37C. Then, the blood vessels were clamped and
the heart was flushed with Krebs buffer and the perfusate collected.
During global in situ ischaemia, we found significant accumulation of suc-
cinate (Figure 4A) and flushing the heart with oxygenated buffer led to a
return to baseline levels of tissue succinate (Figure 4A). Measurement of
succinate in the perfusate following flushing showed loss of succinate
from the heart to the perfusate over the first 2–3 min reperfusion
(Figure 4B), very similar to that for the Langendorff hearts. Comparing
the total amount of succinate released with that present at the onset of
ischaemia and correcting for baseline levels showed that 33% of the
succinate that was present in the tissue at the end of ischaemia was re-
leased upon flushing (Figure 4C). Thus, the succinate efflux seen in the ex
vivo perfused heart is replicated by the more physiological in situ mouse
heart.
To extend this analysis to a large animal model closer in size to human,
we used a pig MI model of I/R in which a 5–0 prolene suture was passed
around the coronary artery and gently snared to block blood flow and
to hold the heart ischaemic for 60 min and then released to reperfuse
the ischaemic tissue with oxygenated blood (Figure 4D). We assessed
the efflux of succinate from the ischaemic tissue into the CS, which
reflects any metabolites released by the ischaemic myocardium upon re-
perfusion, as well as that in the AR and in the JV (Figure 4E and
Supplementary material online, Figure S1). Upon reperfusion, there was a
large increase in the succinate levels in the CS during the first 5 min re-
perfusion (Figure 4E), but not in the blood from the AR or JV
(Supplementary material online, Figure S1). To understand whether the
levels of succinate released from the pig heart during reperfusion were
significant compared to other metabolites, we measured the levels of 40
metabolites in the CS upon reperfusion and in the AR, enabling us to
generate a cardiac release ratio (Figure 4F). This showed that only a few
metabolites were released upon reperfusion of the ischaemic heart tis-
sue of pigs undergoing MI and that prominent among them was succinate
(Figure 4F).
3.4 Succinate efflux can be inhibited
The charged nature of succinate at physiological pH (pKa 4.2 and 5.6)
and the selectivity of its efflux upon reperfusion of ischaemic tissue sug-
gests that its release is carrier-mediated. To assess this hypothesis, we
measured the effect on succinate efflux of the general succinate trans-
port inhibitors succimer and 2-phenylsuccinate, which are structurally
similar to succinate (Figure 5A).24,25 Both these inhibitors decreased suc-
cinate efflux (Figure 5B), with a concomitant increase in succinate
Figure 3 (A and B) Succinate is selectively effluxed from the ischaemic heart upon reperfusion. (A) Release of metabolites in the reperfusion coronary
effluent (1–3 min) from the Langendorff heart, compared to equilibration coronary effluent expressed as cardiac release ratio [(reperfusion - equilibra-
tion)/equilibration]. (B) Plot showing -log10 of the adjusted P-value plotted against the difference in normalized ion counts between equilibration and 1–
3 min reperfusion coronary effluent (n = 5). Plot generated in Prism 8.0 using multiple t-tests corrected for multiple comparisons using the Holm–Sidak
method.
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Figure 4 (A–F) Succinate accumulation and efflux from the ischaemic heart in situ and in vivo. (A) Succinate accumulates during 20 min ischaemia and rap-
idly returns to baseline values after 6 min reperfusion in a murine in situ perfusion model (mean ± SEM, n = 3). Statistical significance was assessed by one-
way ANOVA with Dunnett’s post hoc test [***P < 0.001, relative to control (Normoxia) values]. (B and C) Succinate efflux from the in situ perfused heart
exposed to 20 min ischaemia over the first 6 min of reperfusion (B) and compared to the succinate levels achieved in the heart exposed to 20 min ischae-
mia (C) (mean ± SEM, n = 3). (D) Schematic of porcine MI model and CS blood sampling (E). Succinate is elevated during early reperfusion in the CS in a
porcine MI model. The LAD was occluded by gentle snaring for 60 min before snare released and blood sampled (mean ± SEM, n = 3). Statistical signifi-
cance was assessed by two-way ANOVA with Tukey’s post hoc test (**P < 0.01, ****P < 0.0001). (F) Release of metabolites in the CS at reperfusion (1–
5 min) compared to AR blood expressed as cardiac release ratio [(CS - AR)/AR] in porcine MI model. LAD, left anterior descending.

































































































retention within the heart at the end of the reperfusion period
(Supplementary material online, Figure S2).
3.5 Succinate efflux is enhanced by the
plasma membrane proton gradient
The pH of the ischaemic myocardium can decrease to 6.5, compared
to a pH of 7.4 for the heart perfusate.26,27 Hence, during reperfusion of
the ischaemic heart there will be a pH gradient of1 pH unit across the
plasma membrane, acidic inside. As many metabolite transport pro-
cesses are coupled to proton movement, we next assessed whether this
pH gradient affects succinate efflux.28,29 To do this, we reperfused the
ischaemic heart with pH 6 perfusion buffer to abolish the pH gradient
(Figure 5C). Strikingly, this intervention greatly decreased succinate efflux
(Figure 5C). To further assess the role of the pH gradient in succinate ef-
flux we used a range of ionophores—gramicidin (Hþ, Naþ, Kþ), monen-
sin (Hþ, Naþ), and nigericin (Hþ, Kþ), all of which can disrupt the plasma
membrane pH gradient (Figure 5D). As these ionophores are all large hy-
drophobic molecules they act by inserting into the plasma membrane
and are unlikely to redistribute to intracellular membranes such as the
mitochondrial inner membrane over the timescale of these experi-
ments.30 Thus, their effects are primarily due to disruption to the plasma
membrane pH gradient. All these ionophores significantly decreased suc-
cinate efflux (Figure 5E). These ionophores are large hydrophobic mole-
cules which are unlikely to migrate from the plasma membrane to
disrupt mitochondrial membranes.
In contrast, use of the small protonophores carbonyl cyanide-4-(tri-
fluoromethoxy)phenylhydrazone (FCCP) and 2,4 dinitrophenol (DNP)
significantly disrupted cardiac function (data not shown). We conclude
that succinate efflux upon reperfusion of the ischaemic heart is greatly
enhanced by the pH gradient.
3.6 Succinate efflux from the reperfused
ischaemic heart is mediated by MCT1
The above data show that succinate efflux upon reperfusion of the
ischaemic heart is carrier-mediated and enhanced by a pH gradient.
MCT1, which usually transports lactate in symport with a proton, is a po-
tential carrier for this process.28,31,32 As the first succinate pKa is5.6,33
at the pH within ischaemic tissues (6.5)26,27 10% of the succinate in
the myocardium would be in the monocarboxylate form, which may be
transported by MCT1.6,28,34 Supporting this possibility, expressing
MCT1 in Xenopus oocytes led to succinate uptake into the cells, but only
when incubated in a medium at acidic (pH 6) pH.28 Furthermore,
MCT1 is highly expressed in heart tissue.16
To assess whether MCT1 could mediate succinate efflux in the reper-
fused ischaemic heart, we included lactate in the perfusion buffer to in-
hibit the activity of MCT1. This decreased succinate efflux (Figure 6A).
Next, we reperfused ischaemic hearts with AR-C141990, a selective
MCT1 inhibitor (reffered to as MCTi in the text),35,36 which led to a
dose-dependent decrease in succinate efflux when added to the reperfu-
sion buffer (Figure 6B). A similar effect was seen when hearts were ad-
ministered the MCTi before ischaemia (Figure 6B), which did not alter
the ischaemic levels of succinate (Supplementary material online, Figure
S3). The MCTi also enhanced succinate retention within the reperfused
tissue (Supplementary material online, Figure S4). Succinate efflux was
also reduced by MCT1 inhibition with the MCTi, when it was added
upon reoxygenation of anoxic cardiomyocytes. Here, it decreased succi-
nate efflux by 90% from 1.28± 0.25 to 0.14 ± 0.02 nmol succinate/105
cells (mean ± SEM, n = 6).
To confirm that MCT1 mediates succinate efflux from the ischaemic
heart upon reperfusion, we utilized the MCT1þ/- mouse model.16,37,38
While the MCT1-/- mouse is embryonic lethal, MCT1þ/- mice have40%
reduction in the expression of MCT1 in the heart16 and have no obvious
phenotype in normoxic conditions when compared to MCTþ/þ con-
trols.16,37,38 While the levels of succinate in the MCT1þ/- and MCTþ/þ
hearts were the same after 20 min ischaemia (Supplementary material
online, Figure S3), succinate efflux from reperfused MCT1þ/- hearts was
significantly lower than that of MCT1þ/þ control hearts (Figure 6C). The
levels of succinate retained in the heart after 6 min of reperfusion did not
differ between the MCT1þ/þ and MCT1þ/- hearts (Supplementary mate-
rial online, Figure S5). This result suggests that the reduction in MCT1
level in the MCT1þ/- hearts is sufficient to decrease succinate efflux.
4. Discussion
The accumulation of succinate during ischaemia and its oxidation upon
reperfusion is a key driver of I/R injury.1–5 While succinate is made within
the mitochondrial matrix during ischaemia, most succinate will be pre-
sent in the cytosol at the onset of reperfusion. In addition, it is also clear
that upon reperfusion some of the succinate accumulated during ischae-
mia is released from the tissue upon reperfusion.2,6 Here, we show that
this succinate efflux from the cell is greatly enhanced by the pH gradient
(acidic inside) between the tissue and the circulation upon reperfusion,
and that this efflux is mediated by the monocarboxylate transporter,
MCT1. The best-understood role of MCT1 is as a plasma membrane lac-
tate transporter, which leads to the electroneutral efflux of lactate along
with a proton. At the low pH (6.5) within ischaemic tissue,26,27 10%
of the succinate will be in the monocarboxylate form (pKa  5.6),33
which can then be transported by MCT1,28 presumably because of its
similarity in structure to lactate. In addition, because MCT1 transports a
monocarboxylate in symport with a proton, the pH gradient between
the tissue and the circulation present upon reperfusion of the ischaemic
tissue will also drive succinate efflux. This model of succinate efflux,
which was first suggested by Halestrap and colleagues28 is shown in
Figure 7. Importantly, this work shows that the succinate accumulated in
the heart during ischaemia has two fates: it is either oxidized by the mito-
chondrial respiratory chain or it is released into the circulation, poten-
tially acting as a metabolic signal. A precedent for such signalling is when
circulating succinate is taken up and activates thermogenesis in brown
adipose tissue.14 Thus, elucidating the mechanism of succinate efflux
from the ischaemic heart during reperfusion raises the prospect of tar-
geting MCT1-dependent succinate in heart attack. The kinetics and cur-
rent understanding of succinate transport by MCT1 is poor. While some
initial characterization of this process has been carried out,28 more com-
plete experiments are required to understand the interplay of the pH
gradient and succinate transport.
There are a number of experimental points that should be considered
in interpreting our findings. Perfused heart experiments have a number
of limitations, such as the use of a supra-physiological concentration of
glucose and the lack of fatty acids or other physiological respiratory
substrates.
However, it should be noted that an isolated perfused heart which
was supplied with fatty acids as an energy source accumulates succinate
to a similar extent as hearts perfused with glucose-containing medium.4
The second is that ischaemic hearts in vivo, which had been perfused with
blood prior to ischaemia and were thus respiring on physiological sub-
strates, also accumulate succinate to the same extent as the isolated
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Figure 5 Modulating succinate efflux during reperfusion. (A) Succinate is structurally similar to phenylsuccinate and succimer. (B and C) Langendorff mouse
hearts were exposed to 20min global no-flow ischaemia, before reperfusing for 6min and the succinate measured in the perfusate collected during each minute
of reperfusion. Control reperfusion from Figure 2B (n = 5) and non-specific transport inhibitors added at 1mM succimer (n = 3) and 1mM phenylsuccinate (n = 3)
at the onset and during reperfusion. (C) Mouse hearts were exposed to ischaemia as in Figure 5B but reperfused with buffer at pH 6 (n = 5). (D) Diagram of the
mechanism of action of ionophores gramicidin, monensin, and nigericin. (E) Mouse hearts were exposed to ischaemia as in Figure 5B but reperfused in the presence
of ionophores for 6min (all at 10mM): gramicidin (n = 5), monensin (n = 4), and nigericin (n = 4). All data (B, C, and E) are presented as mean ± SEM and statistical
significance was assessed by two-way ANOVA with Dunnett’s post hoc test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to control reperfusion).








































































.. perfused heart.4,5 The third point is that reperfusion of the ischaemic hu-
man heart,2 or pig heart (this work), in vivo with blood leads to similar ef-
flux of succinate. Thus, our in vitro heart perfusion system shows similar
succinate accumulation during ischaemia and efflux upon reperfusion as
the heart in vivo.
The potential role of succinate efflux as a signal from the ischaemic tis-
sue is supported by the fact that its efflux is carrier-mediated, that succi-
nate accumulates dramatically within ischaemic tissues, and that the
lowered pH within ischaemic tissues facilitates succinate efflux. The accu-
mulation of succinate during ischaemia seems to be a universal phenome-
non and has now been shown by us and many others for hearts from mice,
rats, rabbits, pigs, and humans.1–5 Importantly, this accumulation of succi-
nate during ischaemia also occurs in vivo within tissues utilizing endogenous
substrates, as well as in the Langendorff model, presumably because during
ischaemia the heart relies on glycogen as its main energy source.1–5,39
The succinate efflux from the ischaemic mouse hearts in vivo and ex
vivo was associated with a limited number of other metabolites. The
metabolome of the pig heart attack model mirrored that seen in STEMI
patients,2 suggesting a conserved mechanism of release of these metabo-
lites from the ischaemic heart during reperfusion, with succinate being
particularly elevated in both pigs and humans. We note that the pig is a
widely used model for human cardiac metabolism, and importantly these
were young, healthy animals analysed under tightly controlled condi-
tions, compared to the human subjects1,2 who were all suffering from
cardiac disease. Hence these data indicate that the succinate efflux in the
human subjects was not simply a consequence of pathology. Lactate was
prominent in the perfusate from mouse, a metabolite surprisingly not sig-
nificantly elevated in the human plasma.2 This difference may be due to
global ischaemia in the Langendorff heart compared to regional ischae-
mia in the heart attack models, or due to the high levels of lactate already
present in the plasma masking changes.
The action of succinate ligating its cognate receptor, SUCNR1, and
subsequent immune activation during I/R injury by succinate released
upon reperfusion may contribute to the damage associated with I/R in-
jury (Figure 7).8,9,40,41 However, the pathological role of succinate efflux
and the signalling that occurs on ligation to SUCNR1 are currently
unknown.
Furthermore, inhibition of succinate efflux upon reperfusion with
MCTis might be expected to elevate tissue succinate oxidation and thus
exacerbate I/R injury. To test this possibility, we carried out a preliminary
experiment to assess the effect of the MCTi AR-C141990 on cardiac I/R
injury in an in vivo mouse model of cardiac I/R injury (Supplementary ma-
terial online, Figure S6). Administration of the MCTi upon reperfusion
Figure 6 Succinate efflux during reperfusion is mediated by MCT1.
(A and B) Langendorff hearts were treated as in Figure 5 but reperfused
Figure 6 Continued
in the presence of either (A) 10 mM L-lactate (n = 5) or (B) 1, 10, or
50mM AR-C141990 (MCTi; n = 3–5). AR-C141990 was also used
as a pre-treatment by infusing it during the equilibration phase prior
to inducing ischaemia (MCTi-Pre at 50mM; n = 5) (all mean ± SEM).
Statistical significance was assessed by two-way ANOVA with
Dunnett’s post hoc test (*P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 relative to standard reperfusion). (C) Succinate ef-
flux from MCT1þ/- and MCTþ/þmouse hearts exposed to 20 min is-
chaemia upon reperfusion (mean ± SEM, MCTþ/þ n = 7, MCTþ/-
n = 5). Statistical significance was assessed by two-way ANOVA
with Dunnett’s post hoc test (*P < 0.05, **P < 0.01 relative to





























































..was protective, despite the elevated tissue levels of succinate it caused in
the isolated perfused heart (Supplementary material online, Figure S4).
Further work is required to understand the mechanistic basis of this pro-
tection. One possibility is that the lack of lactate efflux has an impact on
the cell, perhaps by its impact on glycolytic flux or cell pH. One possibil-
ity is that these factors disrupt mitochondrial succinate oxidation or
ROS production during reperfusion. Future work will be required to de-
termine fully the (patho)physiological roles of MCT1-dependent succi-
nate efflux.
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Translational perspective
In this study, we demonstrate that succinate efflux upon reperfusion of the ischaemic myocardium is mediated by the monocarboxylate transporter
1 and is enhanced by the ischaemic acidification of the heart. These findings are an important advance in understanding how succinate is released
upon reperfusion of ischaemic organs. While this pathway is therapeutically tractable, greater understanding of the effects of succinate release is re-
quired before exploring this possibility.
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